Suven Life Sciences Limited (BOM:530239)

Market Cap	70.72B +32.5%
Revenue (ttm)	71.15M +6.9%
Net Income	-2.76B
EPS	-12.13
Shares Out	263.72M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	70,208
Open	259.25
Previous Close	259.70
Day's Range	254.55 - 271.35
52-Week Range	124.35 - 303.00
Beta	0.84
Analysts	Strong Buy
Price Target	306.00 (+14.12%)
Earnings Date	Aug 11, 2026

About Suven Life Sciences

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 recepto...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1989
• Employees: 138
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 530239

Financial Performance

In fiscal year 2026, Suven Life Sciences's revenue was 71.15 million, an increase of 6.89% compared to the previous year's 66.56 million. Losses were -2.76 billion, 71.9% more than in 2025.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 21, 2026

Data Sources Report a data error